Catheter Precision, Inc. (VTAK) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-23

Key Insights

Company closed $3.47M Series C-2 preferred stock financing on April 21, 2026, after obtaining stockholder approval on April 15, 2026, indicating successful capital raise to fund operations and growth initiatives.
Acquisition of Fly Flyte, Inc. completed with issuance of 11,028 shares of Series D Convertible Preferred Stock (valued at $11.028M) to SEG Jets LLC and Creatd, Inc., representing significant dilution but strategic expansion of company portfolio.
Conversion prices set at $0.883 (Series C-2) and $1.1038 (Series D) with floor price of $0.35 per share suggest current stock trading below conversion prices, indicating potential near-term dilution risk if stock appreciates.
Multiple rounds of financing and M&A activity (February, March, and April 2026) demonstrate aggressive growth strategy but also indicate substantial equity dilution for existing shareholders with multiple preferred stock tranches.

Want the newest filings?

This analysis covers the filing from 2026-04-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-15

Catheter Precision, Inc. received shareholder approval for the issuance of shares underlying various series of convertible preferred stock, indicating potential financing and growth initiatives.
The company received approval to amend its certificate of incorporation to effect a reverse stock split, which could improve stock liquidity and valuation.
The shareholder meeting was well-attended, with nearly 50% of outstanding shares represented, suggesting investor engagement with the company's strategic direction.

Filed: 2026-01-08

Catheter Precision, Inc. has extended the maturity dates of its outstanding short-term promissory notes to January 2028 and January 2029, providing the company with additional financial flexibility.
The extended maturity dates were granted to insiders, including the Executive Chair and CEO, David A. Jenkins, and his affiliates, indicating their continued support and commitment to the company.
The company's reliance on related party financing raises concerns about its financial stability and independence, which investors should monitor closely.

Other reports for Catheter Precision, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.